Početna stranicaATHA • NASDAQ
add
Athira Pharma Inc
0,64 $
Poslije radnog vremena:(0,47 %)−0,0030
0,64 $
Zatvoreno: 22. stu, 19:49:03 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
0,66 $
Dnevni raspon
0,63 $ - 0,66 $
Godišnji raspon
0,41 $ - 4,30 $
Tržišna kapitalizacija
24,64 mil. USD
Prosječna količina
9,62 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 25,49 mil. | −27,25 % |
Neto dohodak | −28,74 mil. | 12,83 % |
Neto profitabilnost | — | — |
Zarada po dionici | — | — |
EBITDA | −25,25 mil. | 27,44 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 68,86 mil. | −60,19 % |
Ukupna imovina | 86,25 mil. | −53,30 % |
Ukupne obveze | 28,66 mil. | −4,25 % |
Ukupni kapital | 57,58 mil. | — |
Dionice u optjecaju | 38,67 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,44 | — |
Povrat imovine | −64,54 % | — |
Povrat kapitala | −88,74 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −28,74 mil. | 12,83 % |
Gotovina od poslovanja | −23,02 mil. | 4,01 % |
Gotovina iz ulaganja | 18,04 mil. | −12,81 % |
Gotovina iz financiranja | 12,00 tis. | — |
Neto promjena novca | −4,97 mil. | −50,94 % |
Slobodan tok novca | −10,13 mil. | 13,86 % |
Više
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Osnovano
2011
Web-lokacija
Zaposlenici
66
